Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

Phase 2

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Biological: BIIB019 (Daclizumab High Yield Process)
Drug: Placebo

First Posted Date: 2009-03-27

Last Posted Date: 2016-08-30

Lead Sponsor: Biogen

Target Recruit Count: 517

Registration Number: NCT00870740

Locations: 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom

BG9928 in Subjects With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

First Posted Date: 2009-03-09

Last Posted Date: 2010-01-27

Lead Sponsor: Biogen

Target Recruit Count: 23

Registration Number: NCT00858156

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Phase 1

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: BG00012

First Posted Date: 2009-02-05

Last Posted Date: 2018-02-15

Lead Sponsor: Biogen

Target Recruit Count: 48

Registration Number: NCT00837785

Locations: 🇩🇪
Research Site, Berlin, Germany

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: dimethyl fumarate
Drug: Placebo

First Posted Date: 2009-02-04

Last Posted Date: 2020-12-31

Lead Sponsor: Biogen

Target Recruit Count: 1736

Registration Number: NCT00835770

Locations: 🇬🇧
Research Site, Stoke on Trent, United Kingdom
🇺🇸
research Site, Mesa, Arizona, United States

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: natalizumab

First Posted Date: 2009-01-29

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Registration Number: NCT00831649

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Device: single-use autoinjector with a prefilled liquid Avonex syringe
Device: Avonex prefilled syringe via manual IM injection
Drug: BG9418 (interferon beta-1a)

First Posted Date: 2009-01-23

Last Posted Date: 2014-06-03

Lead Sponsor: Biogen

Target Recruit Count: 95

Registration Number: NCT00828204

Locations: 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸
Research Site, Charleston, West Virginia, United States
🇺🇸
Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States

and more 2 locations

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: BG0002 (natalizumab)

First Posted Date: 2009-01-07

Last Posted Date: 2014-06-27

Lead Sponsor: Biogen

Target Recruit Count: 30

Registration Number: NCT00818038

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BG00012
Drug: placebo

First Posted Date: 2008-12-18

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Target Recruit Count: 153

Registration Number: NCT00810836

Locations: 🇸🇰
Research Site, Piestany, Slovakia

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Phase 4

Withdrawn

Conditions: Crohn's Disease

First Posted Date: 2008-12-03

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Registration Number: NCT00801125

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Lumiliximab + FCR
Drug: FCR

First Posted Date: 2008-12-03

Last Posted Date: 2015-10-02

Lead Sponsor: Biogen

Target Recruit Count: 40

Registration Number: NCT00801060

Locations: 🇺🇸
University of Florida/Pulmonary, Critical Care & Sleep Medicine, Gainesville, Florida, United States
🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Vanderbilt University Medical Center-IPF Program, Nashville, Tennessee, United States

and more 3 locations

Home Terms & Conditions Privacy Policy